» Articles » PMID: 16288054

Expression Profiling of Serous Low Malignant Potential, Low-grade, and High-grade Tumors of the Ovary

Overview
Journal Cancer Res
Specialty Oncology
Date 2005 Nov 17
PMID 16288054
Citations 119
Authors
Affiliations
Soon will be listed here.
Abstract

Papillary serous low malignant potential (LMP) tumors are characterized by malignant features and metastatic potential yet display a benign clinical course. The role of LMP tumors in the development of invasive epithelial cancer of the ovary is not clearly defined. The aim of this study is to determine the relationships among LMP tumors and invasive ovarian cancers and identify genes contributing to their phenotypes. Affymetrix U133 Plus 2.0 microarrays (Santa Clara, CA) were used to interrogate 80 microdissected serous LMP tumors and invasive ovarian malignancies along with 10 ovarian surface epithelium (OSE) brushings. Gene expression profiles for each tumor class were used to complete unsupervised hierarchical clustering analyses and identify differentially expressed genes contributing to these associations. Unsupervised hierarchical clustering analysis revealed a distinct separation between clusters containing borderline and high-grade lesions. The majority of low-grade tumors clustered with LMP tumors. Comparing OSE with high-grade and LMP expression profiles revealed enhanced expression of genes linked to cell proliferation, chromosomal instability, and epigenetic silencing in high-grade cancers, whereas LMP tumors displayed activated p53 signaling. The expression profiles of LMP, low-grade, and high-grade papillary serous ovarian carcinomas suggest that LMP tumors are distinct from high-grade cancers; however, they are remarkably similar to low-grade cancers. Prominent expression of p53 pathway members may play an important role in the LMP tumor phenotype.

Citing Articles

rs66651343 and rs12909095 confer lung cancer risk by regulating CCNDBP1 expression.

Shi Q, Ruan J, Yang Y, Shi X, Liu S, Wang H PLoS One. 2023; 18(4):e0284347.

PMID: 37058478 PMC: 10104294. DOI: 10.1371/journal.pone.0284347.


A phase II evaluation of temsirolimus with carboplatin and paclitaxel followed by temsirolimus consolidation in clear cell ovarian cancer: An NRG oncology trial.

Farley J, Brady W, OMalley D, Fujiwara K, Yonemori K, Bonebrake A Gynecol Oncol. 2022; 167(3):423-428.

PMID: 36244829 PMC: 9789681. DOI: 10.1016/j.ygyno.2022.10.006.


MAPK Pathway Genetic Alterations Are Associated with Prolonged Overall Survival in Low-Grade Serous Ovarian Carcinoma.

Manning-Geist B, Gordhandas S, Liu Y, Zhou Q, Iasonos A, Da Cruz Paula A Clin Cancer Res. 2022; 28(20):4456-4465.

PMID: 35443055 PMC: 9582036. DOI: 10.1158/1078-0432.CCR-21-4183.


Multi-Marker Immunofluorescent Staining and PD-L1 Detection on Circulating Tumour Cells from Ovarian Cancer Patients.

Asante D, Morici M, Mohan G, Acheampong E, Spencer I, Lin W Cancers (Basel). 2021; 13(24).

PMID: 34944844 PMC: 8699768. DOI: 10.3390/cancers13246225.


Differential gene expression identifies a transcriptional regulatory network involving ER-alpha and PITX1 in invasive epithelial ovarian cancer.

Li Y, Jaiswal S, Kaur R, Alsaadi D, Liang X, Drews F BMC Cancer. 2021; 21(1):768.

PMID: 34215221 PMC: 8254236. DOI: 10.1186/s12885-021-08276-8.